Newly added drugs in national reimbursement drug list vs Clinical trial registrations in China
In 2025, newly added drugs in national reimbursement drug list in China stood at 114, against 5,215 for clinical trial registrations.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Newly added drugs in national reimbursement drug list and Clinical trial registrations
Unit: count · 6 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Newly added drugs in national reimbursement drug list | as of 7 Dec 2025 | Actual | 114 |
| Newly added drugs in national reimbursement drug list | as of 28 Nov 2024 | Actual | 91 |
| Clinical trial registrations | 2025 | Actual | 5,215 |
| Clinical trial registrations | 2023 | Actual | 4,300 |
| Clinical trial registrations | 2022 | Actual | 3,410 |
| Clinical trial registrations | 2021 | Actual | 3,358 |
Shared periods
Side by side
Only one period is published for both series in China. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Newly added drugs in national reimbursement drug list
Total count of new drug varieties incorporated into a national reimbursement drug list during a catalog adjustment cycle.
2 observations in China · source organisations: NHSA, SCIO
Clinical trial registrations
Number of clinical trials registered on the International Clinical Trials Registry Platform.
4 observations in China · source organisations: State Council, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring